Medicines Classification




12 FEBRUARY 2009

NEW ZEALAND GAZETTE, No. 16

Schedule

Oxiconazole; except when specified elsewhere in this Schedule

Palifermin

Paliperidone

Panitumumab

Paracetamol; except when specified elsewhere in this Schedule

Paricalcitol

Pegvisomant

Pheniramine; except when specified elsewhere in this Schedule

Phenyltoloxamine

Picric acid

Polysulfated glycosaminoglycans; for injection except in intraocular viscoelastic products

Promethazine; except when specified elsewhere in this Schedule

Pyridoxal; in medicines containing more than 200 milligrams per recommended daily dose

Pyridoxamine; in medicines containing more than 200 milligrams per recommended daily dose

Pyrvinium

Raltegravir

Ranibizumab

Ranitidine; except when specified elsewhere in this Schedule; except in medicines containing 150 milligrams or less per dose unit which have received the consent of the Minister or the Director-General to their distribution as general sale medicines and which are sold in the manufacturer’s original pack containing not more than 7 days’ supply

Rasagilin

Rifampicin

Riluzole

Rimexolone

Rimonabant

Ruboxistaurin

Sabadilla

Schoenocoulon officinale

Scopolia carniolica

Selenium; except when specified elsewhere in this Schedule; except for oral use in medicines containing 150 micrograms or less per recommended daily dose; except for external use in medicines containing 3.5% or less of selenium sulphide

Sitagliptin

Sitaxentan

Sorafenib

Sumatriptan; except when specified elsewhere in this Schedule

Sugammadex

Sunitinib

Telbivudine

Thenyldiamine

Tipepidine

Tiprinavir

Tolpropamine

Tocilizumab

Trimeprazine; except when specified elsewhere in this Schedule

Trinitrophenol

Triprolidine; except when specified elsewhere in this Schedule

Varenicline

Vildagliptin

Vitamin A; for internal use in medicines containing more than 3,000 micrograms of retinol equivalents per recommended daily dose except in parenteral nutrition replacement preparations; for external use in medicines containing more than 1%

Vitamin D; for internal use in medicines containing more than 25 micrograms per recommended daily dose except in parenteral nutrition replacement preparations

Zinc; for internal use in medicines containing more than 25 milligrams per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs which have received the consent of the Minister or the Director-General to their distribution as general sale medicines and which are sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except in parenteral nutrition replacement preparations

Zonisamide

Schedule 2

Restricted Medicines

Aspirin; in slow release forms; in enteric coated forms containing more than 300 milligrams per dose form; except when specified elsewhere in this Schedule

Azatadine; for oral use in adults and children over 2 years of age

Azelastine; in medicines for ophthalmic use containing 0.05% or less

Brompheniramine; for oral use medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Butoconazole; for vaginal use

Chlorpheniramine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Dexchlorpheniramine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Diphenhydramine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Diphenylpyraline; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Doxylamine; for oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this Schedule

Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack.

Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units and which have received the consent of the Minister or the Director-General to their



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2009, No 16





✨ LLM interpretation of page content

🏥 Classification of Medicines (continued from previous page)

🏥 Health & Social Welfare
Medicines, Classification, Prescription, Restricted, Pharmacy-only